Subscribe To

Price Alert Latest News Economic Calendar News

ANAB / AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne

AnaptysBio Inc's (NASDAQ: ANAB) Phase 2 ACORN trial of imsidolimab for moderate-to-severe acne did not demonstrate efficacy over placebo on primary or secondary endpoints. Imsidolimab was generally safe, well-tolerated, and no imsidolimab-related serious or severe adverse events. Read More

Demo Live Account See Partner Details

Content Topics

Anaptysbio

Discontinue

Imsidolimab

Development

Moderate to severe

Stock

ANAB

Posted: Mar 15 2022, 08:22

Author Name: Benzinga

ANAB News

By GlobeNewsWire
November 1, 2023

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative

By GlobeNewsWire
October 11, 2023

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative

By Reuters
October 9, 2023

AnaptysBio's skin disease drug meets main goal in late-stage study

AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study.

By GlobeNewsWire
September 12, 2023

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative

By Seeking Alpha
July 7, 2023

AnaptysBio: Despite Early Successes, Current Situation Does Not Impress

AnaptysBio, Inc. had major deals with big pharma in past years. However, its current programs are not that convincing. They have a lot of cash from ea

By Zacks Investment Research
May 11, 2023

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to los

By Seeking Alpha
March 30, 2023

AnaptysBio: Upside Could Be Lying Ahead Very Nicely

US-listed biotech stocks are trading even lower than before on fears of a banking system collapse, creating an opportunity to add to positions and tak

By GlobeNewsWire
November 9, 2022

AnaptysBio to Participate in Upcoming November Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.